Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Net Margin (2016 - 2025)

Corcept Therapeutics' Net Margin history spans 10 years, with the latest figure at 11.83% for Q4 2025.

  • For Q4 2025, Net Margin fell 488.0% year-over-year to 11.83%; the TTM value through Dec 2025 reached 12.89%, down 781.0%, while the annual FY2025 figure was 12.89%, 781.0% down from the prior year.
  • Net Margin for Q4 2025 was 11.83% at Corcept Therapeutics, up from 9.32% in the prior quarter.
  • Across five years, Net Margin topped out at 33.96% in Q3 2022 and bottomed at 9.32% in Q3 2025.
  • The 5-year median for Net Margin is 23.13% (2023), against an average of 22.21%.
  • The largest annual shift saw Net Margin tumbled -1639bps in 2022 before it surged 697bps in 2023.
  • A 5-year view of Net Margin shows it stood at 32.44% in 2021, then tumbled by -51bps to 16.04% in 2022, then soared by 43bps to 23.01% in 2023, then fell by -27bps to 16.71% in 2024, then dropped by -29bps to 11.83% in 2025.
  • Per Business Quant, the three most recent readings for CORT's Net Margin are 11.83% (Q4 2025), 9.32% (Q3 2025), and 17.8% (Q2 2025).